November 2020 Research Update : Creyon Bio Takes on FOXG1 for ASOs!
November 2020 FOXG1 Research Foundation Research Update: Two Biotech companies are investing in FOXG1 syndrome for gene therapy and ASO therapy. FOXG1 Research is moving into screening drugs and testing potential therapies with a newly assembled consortium of esteemed scientists.
Taysha Gene Therapies Takes on FOXG1 Syndrome!
Taysha Gene Therapies adds FOXG1 syndrome to the pipeline of neurodegenerative CNS disorders; Taysha will develop gene developing gene replacement therapy (TSHA-117) for FOXG1 syndrome, using their novel miRNA target panel.
The FOXG1 Science Symposium 2020 - Recap
The virtual FOXG1 Science Symposium 2020 was a tremendous success in demonstrating the work towards advancing science to find a cure for FOXG1 syndrome. Scientists from Tokyo, the UK, Italy, California and more gathered with Biopharma industry executives and FOXG1 caregivers to share data and engage in collaborative discussions towards disease-modifying therapies. Read the recap here and watch the panel discussions.